Tag
Moderna and Merck announced the success of their mRNA cancer vaccine in a Phase 3 melanoma trial, which could establish a new personalized treatment paradigm for cancer.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.